Asad Ullah

Department of Pathology and Laboratory Medicine, Texas Tech University Health Sciences Center, Lubbock , TX, USA

Abdul Qahar Khan Yasinzai

Department of Medicine, Bolan Medical College, Quetta, Pakistan

Naema Daino

Medical College of Georgia, Augusta, GA, USA

Bisma Tareen

Department of Medicine, Bolan Medical College, Quetta, Pakistan

Zulfiqar Haider Jogezai

Aga University Medical College Pakistan

Haleema Sadia

Khyber Medical College, Pakistan

Nimra Jamil

Department of Medicine, Bolan Medical College, Quetta, Pakistan

Girahnaz Baloch

Department of Medicine, Bolan Medical College, Quetta, Pakistan

Adil Karim

Department of Internal Medicine, Integris Baptist Health, Oklahoma City, OK, USA

Kaleemullah Badini

Bolan Medical College

Agha Wali

Department of Medicine, Bolan Medical College, Quetta, Pakistan

Abdul Waheed

Department of Surgery, San Joaquin General Hospital, French Camp, CA, USA

Marjan Khan

Department of Internal Medicine, Marshfield Clinic, Marshfield, WI, USA

Bina Asif

Bannu Medical College, Bannu, Pakistan

Kaleemullah Kakar

Department of Medicine, Bolan Medical College, Quetta, Pakistan

Saleh Heneidi

Department of Pathology, Kaiser Permanente South Bay, Los Angeles, CA, USA

Ferouze Sidhwa

San Joaquin General Hospital, French Camp, CA

Nabin Raj Karki

Department of Hematology and Medical Oncology, University of South Alabama, Mobile, AL, USA

Keywords

COSMIC; next-generation sequencing; papillary renal cell carcinoma; SEER

References

1. Moch H, Amin MB, Berney DM, Compérat EM, Gill AJ, Hartmann A, et al. The 2022 World Health Organization classification of tumours of the urinary system and male genital organs—Part A: Renal, penile, and testicular tumours. Eur Urol. 2022;82(5):458–68. https://doi.org/10.1016/j.eururo.2022.06.016
2. Mendhiratta N, Muraki P, Sisk AE Jr, Shuch B. Papillary renal cell carcinoma: Review. Urol Oncol. 2021;39(6):327–37. https://doi.org/10.1016/j.urolonc.2021.04.013
3. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics., 2022. CA Cancer J Clin. 2022;72(1):7–33. https://doi.org/10.3322/caac.21708
4. Lobo J, Ohashi R, Amin MB, Berney DM, Compérat EM, Cree IA, et al. WHO 2022 landscape of papillary and chromophobe renal cell carcinoma. Histopathology. 2022;81(4):426–38. https://doi.org/10.1111/his.14700
5. Angori S, Lobo J, Moch H. Papillary renal cell carcinoma: Current and controversial issues. Curr Opin Urol. 2022;32(4):344–51. https://doi.org/10.1097/MOU.0000000000001000
6. Cornejo KM, Dong F, Zhou AG, Wu CL, Young RH, Braaten K, et al. Papillary renal cell carcinoma: Correlation of tumor grade and histologic characteristics with clinical outcome. Human Pathol. 2015;46(10):1411–7. https://doi.org/10.1016/j.humpath.2015.07.001
7. Sukov WR, Lohse CM, Leibovich BC, Thompson RH, Cheville JC. Clinical and pathological features associated with prognosis in patients with papillary renal cell carcinoma. J Urol. 2012;187(1):54–9. https://doi.org/10.1016/j.juro.2011.09.053
8. Akhtar M, Al-Bozom IA, Al Hussain T. Papillary renal cell carcinoma (PRCC): An update. Adv Anat Pathol. 2019;26(2):124–32. https://doi.org/10.1097/PAP.0000000000000220
9. Skinner DG, Colvin RB, Vermillion CD, Pfister RC, Leadbetter WF. Diagnosis and management of renal cell carcinoma. A clinical and pathologic study of 309 cases. Cancer. 1971;28(5):1165–77. https://doi.org/10.1002/1097-0142(1971)28:53.0.co;2-g
10. Abou Elkassem AM, Lo SS, Gunn AJ, Shuch BM, Dewitt-Foy ME, Abouassaly R, et al. Role of imaging in renal cell carcinoma: A multidisciplinary perspective. Radiographics. 2021;41(5):1387–407. https://doi.org/10.1148/rg.2021200202
11. Chiarello MA, Mali RD, Kang SK. Diagnostic accuracy of MRI for detection of papillary renal cell carcinoma: A systematic and meta-analysis. AJR Am J Roentgenol. 2018;211(4), 812–21. https://doi.org/10.2214/AJR.17.19462
12. Srinivasan R, Hammerich K. Papillary renal cell carcinoma. In: Malouf G, Tannir N, editors. Rare kidney tumors. Cham: Springer; 2019. p. 53–63.
13. Murugan P, Jia L, Dinatale RG, Assel M, Benfante N, Al-Ahmadie HA, et al. Papillary renal cell carcinoma: A single institutional study of 199 cases addressing classification, clinicopathologic and molecular features, and treatment outcome. Mod Pathol. 2022;35(6):825–35. https://doi.org/10.1038/s41379-021-00990-9
14. Patel HD, Pierorazio PM, Johnson MH, Sharma R, Iyoha E, Allaf ME, et al. Renal functional outcomes after surgery, ablation, and active surveillance of localized renal tumors: A systematic review and meta-analysis. Clin J Am Soc Nephrol. 2017;12(7):1057–69. https://doi.org/10.2215/CJN.11941116
15. Van Poppel H, Da Pozzo L, Albrecht W, Matveev V, Bono A, Borkowski A, et al. A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol. 2011;59(4):543–52. https://doi.org/10.1016/j.eururo.2010.12.013
16. Vera-Badillo FE, Templeton AJ, Duran I, Ocana A, de Gouveia P, Aneja P, et al. Systemic therapy for non-clear cell renal cell carcinomas: A systematic review and meta-analysis. Eur Urol. 2015;67(4), 740–9. https://doi.org/10.1016/j.eururo.2014.05.010
17. Choueiri TK, Heng DYC, Lee JL, Cancel M, Verheijen RB, Mellemgaard A, et al. Efficacy of Savolitinib vs sunitinib in patients with MET-driven papillary renal cell carcinoma: The SAVOIR phase 3 randomized clinical trial. JAMA Oncol. 200;6(8):1247–55. https://doi.org/10.1001/jamaoncol.2020.2218
18. de Vries-Brilland M, McDermott DF, Suárez C, Powles T, Gross-Goupil M, Ravaud A, et al. Checkpoint inhibitors in metastatic papillary renal cell carcinoma. Cancer Treat Rev. 2022;99:102228. https://doi.org/10.1016/j.ctrv.2021.102228
19. Martínez Chanzá N, Xie W, Asim Bilen M, Dzimitrowicz H, Burkart J, Geynisman DM, et al. Cabozantinib in advanced non-clear-cell renal cell carcinoma: A multicentre, retrospective, cohort study. Lancet Oncol. 2019;20(4):581–90. https://doi.org/10.1016/S1470-2045(18)30907-0
20. Pal SK, Tangen C, Thompson IM Jr, Balzer-Haas N, George DJ, Heng DYC, et al. A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: A randomised, open-label, phase 2 trial. Lancet. 2021;397(10275:695–703. https://doi.org/10.1016/S0140-6736(21)00152-5
21. Escudier B, Molinie V, Bracarda S, Maroto P, Szczylik C, Nathan P, et al. Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis. Eur J Cancer. 2016;69:226–35. https://doi.org/10.1016/j.ejca.2016.08.004
22. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2016;356(22):2271–81. https://doi.org/10.1056/NEJMoa066838
23. Dutcher JP, de Souza P, McDermott D, Figlin RA, Berkenblit A, Thiele A, et al. Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol. 2009;26(2):202–9. https://doi.org/10.1007/s12032-009-9177-0
24. Klatte T, Pantuck AJ, Said JW, Seligson DB, Rao NP, LaRochelle JC, et al. Cytogenetic and molecular tumor profiling for type 1 and type 2 papillary renal cell carcinoma. Clin Cancer Res. 2009;15(4):1162–9. https://doi.org/10.1158/1078-0432.CCR-08-1229
25. Cancer Genome Atlas Research Network, Linehan WM, Spellman PT, Ricketts CJ, Creighton CJ, Fei SS, et al. Comprehensive molecular characterization of papillary renal-cell carcinoma. N Engl J Med. 2016;374(2):135–45. https://doi.org/10.1056/NEJMoa1505917
26. Ledezma RA, Negron E, Paner GP, Rjepaj C, Lascano D, Haseebuddin M, et al. Clinically localized type 1 and 2 papillary renal cell carcinomas have similar survival outcomes following surgery. World J Urol. 2016;34(5):687–93. https://doi.org/10.1007/s00345-015-1692-3
27. Park I, Shim YS, Go H, Hong BS, Lee JL. Long-term response of metastatic hereditary leiomyomatosis and renal cell carcinoma syndrome associated renal cell carcinoma to bevacizumab plus erlotinib after temsirolimus and axitinib treatment failures. BMC Urol. 2019;19(1):51. https://doi.org/10.1186/s12894-019-0484-2
28. Choi Y., Keam, B., Kim, M., Yoon, S., Kim, D., Choi, J. G., et al. Bevacizumab plus Erlotinib combination therapy for advanced hereditary leiomyomatosis and renal cell carcinoma-associated renal cell carcinoma: A multicenter retrospective analysis in Korean patients. Cancer Res Treat. 2019;51(4):1549–56. https://doi.org/10.4143/crt.2019.086
29. Schrader AJ, Rauer-Bruening S, Olbert PJ, Hegele A, Rustemeier J, Timmesfeld N, et al. Incidence and long-term prognosis of papillary renal cell carcinoma. J Cancer Res Clin Oncol. 2009;135(6):799–805. https://doi.org/10.1007/s00432-008-0515-y
30. Ronnen EA, Kondagunta GV, Ishill N, Spodek L, Russo P, Reuter V, et al. Treatment outcome for metastatic papillary renal cell carcinoma patients. Cancer. 2006;107(11):2617–21. https://doi.org/10.1002/cncr.22340
31. Pan H, Ye L, Zhu Q, Yang Z, Hu M. The effect of the papillary renal cell carcinoma subtype on oncological outcomes. Sci Rep. 2020;10:21073. https://doi.org/10.1038/s41598-020-78174-9
32. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511(7511):543–50. https://doi.org/10.1038/nature13385
33. Wolf J, Seto T, Han JY, Reguart N, Garon EB, Groen HJM, et al. Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer. N Engl J Med. 2020;383(10):944–57. https://doi.org/10.1056/NEJMoa2002787
34. Camidge DR, Otterson GA, Clark JW, Ignatius Ou SH, Weiss J, Ades S, et al. Crizotinib in patients with MET-amplified NSCLC. J Thorac Oncol. 2021;16(6):1017–29. https://doi.org/10.1016/j.jtho.2021.02.010
35. Choueiri TK, Heng DYC, Lee JL, Cancel M, Verheijen RB, Mellemgaard A, et al. Efficacy of savolitinib vs sunitinib in patients with MET-driven papillary renal cell carcinoma: The SAVOIR Phase 3 randomized clinical Trial. JAMA Oncol. 2020;6(8):1247–55. https://doi.org/10.1001/jamaoncol.2020.2218
36. Yang XJ, Tan MH, Kim HL, Ditlev JA, Betten MW, Png CE, et al. A molecular classification of papillary renal cell carcinoma. Cancer Res. 2020;65(13):5628–37. https://doi.org/10.1158/0008-5472.CAN-05-0533
37. Srivastava A, Doppalapudi SK, Patel HV, Srinivasan R, Singer EA. The roaring 2020s: A new decade of systemic therapy for renal cell carcinoma. Curr Opin Oncol. 2022;34(3):234–42. https://doi.org/10.1097/CCO.0000000000000831
38. Ronnen EA, Kondagunta GV, Ishill N, Spodek L, Russo P, Reuter V, et al. Treatment outcome for metastatic papillary renal cell carcinoma patients. Cancer. 2006;107(11):2617–21. https://doi.org/10.1002/cncr.22340